Purified
Candida albicans sterol 14-

demethylase (CaCYP51) bound
the CYP51 substrates lanosterol and eburicol, producing type
I binding spectra with
Ks values of 11 and 25 µM, respectively,
and a
Km value of 6 µM for lanosterol. Azole binding to
CaCYP51 was "tight" with both the type II spectral intensity
(
Amax) and the azole concentration required to obtain a half-
Amax being proportional to the CaCYP51 concentration. Tight
binding of fluconazole and itraconazole was confirmed by 50%
inhibitory concentration determinations from CYP51 reconstitution
assays. CaCYP51 had similar affinities for clotrimazole, econazole,
itraconazole, ketoconazole, miconazole, and voriconazole, with
Kd values of 10 to 26 µM under oxidative conditions, compared
with 47 µM for fluconazole. The affinities of CaCYP51
for fluconazole and itraconazole appeared to be 4- and 2-fold
lower based on CO displacement studies than those when using
direct ligand binding under oxidative conditions. Econazole
and miconazole were most readily displaced by carbon monoxide,
followed by clotrimazole, ketoconazole, and fluconazole, and
then voriconazole (7.8 pmol min
–1), but itraconzole could
not be displaced by carbon monoxide. This work reports in depth
the characterization of the azole binding properties of wild-type
C. albicans CYP51, including that of voriconazole, and will
contribute to effective screening of new therapeutic azole antifungal
agents. Preliminary comparative studies with the I471T CaCYP51
protein suggested that fluconazole resistance conferred by this
mutation was through a combination of increased turnover, increased
affinity for substrate, and a reduced affinity for fluconazole
in the presence of substrate, allowing the enzyme to remain
functionally active, albeit at reduced velocity, at higher fluconazole
concentrations.
Antimicrobial Agents and Chemotherapy, October 2010, p. 4235-4245, Vol. 54, No. 10
0066-4804/10/$12.00+0 doi:10.1128/AAC.00587-10
No comments:
Post a Comment